Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
about
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
description
A clinical trial related to cancer immunotherapy, retrieved from clinicaltrials.gov
@en
klinisch onderzoek
@nl
name
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
@en
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
@nl
type
label
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
@en
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
@nl
prefLabel
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
@en
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
@nl
P1050
P3098
NCT03130764